SecurityTXRH / Texas Roadhouse, Inc. (882681109)
IndustryRestaurants, Dining, and Eating Places
Common Shares Outstanding71,355,927 shares (as of 2017-12-26)
Total Insiders10
Total Directors6
Total Officers5

Stock Insider Trading (from SEC Form 4)

Texas Roadhouse, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

TXRH / Texas Roadhouse, Inc. insiders include Colosi Scott Matthew, WIDMER KATHY, Robinson Tonya Ramsey James, Catlett Celia, Jacobsen S. Chris, Taylor Wayne Kent, MOORE GREGORY N, PARKER JAMES F, ZARLEY JAMES R, and .

Insider Roster

Insider Dir Off 10% Shares Owned
Robinson Tonya CFO
X 4
Colosi Scott Matthew President and CFO
X 58,202
WIDMER KATHY Director
X
ZARLEY JAMES R Director
X
PARKER JAMES F Director
X
MOORE GREGORY N Director
X
Taylor Wayne Kent Chairman, CEO, Director
X X 3,779,473
Jacobsen S. Chris Chief Marketing Officer
X 16,533
Catlett Celia General Counsel
X 12,429
Ramsey James Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-08 4 Colosi Scott Matthew G D -5,000 58,202
2018-03-26 4 WIDMER KATHY S D 56.51 -8,000 10,950 618,784
2018-02-23 4 ZARLEY JAMES R Zarley Investments, LP S I 56.91 -2,400 23,800 1,354,458
2018-02-23 4 ZARLEY JAMES R Zarley Family Foundation S I 56.80 -8,500 23,800 1,351,840
2018-02-16 4 Colosi Scott Matthew S D 58.55 -10,644 63,202 3,700,477
2018-02-15 4 Colosi Scott Matthew F D 57.16 -19,298 73,846
2018-02-15 4 Colosi Scott Matthew A D 40,585 93,144
2018-02-15 4 Taylor Wayne Kent F D 57.16 -53,441 3,779,473
2018-02-15 4 Taylor Wayne Kent A D 114,991 3,832,914
2018-01-26 4 MOORE GREGORY N Moore Family Trust G I 8,500 87,650
2018-01-26 4 MOORE GREGORY N G D -8,500 0
2018-01-29 4 Jacobsen S. Chris S D 60.00 -366 16,533 991,980
2018-01-26 4 Jacobsen S. Chris S D 60.00 -1,134 16,899 1,013,940
2018-01-12 4 Jacobsen S. Chris S D 57.96 -1,000 18,033 1,045,193
2018-01-11 4 Colosi Scott Matthew G D -4,412 52,559
2018-01-08 4 Catlett Celia S D 56.11 -6,337 12,429 697,391
2018-01-08 4 Catlett Celia F D 57.16 -7,571 18,766
2018-01-08 4 Catlett Celia M D 20,000 26,337
2018-01-08 4 Taylor Wayne Kent F D 57.16 -5,308 3,717,923
2018-01-08 4 Taylor Wayne Kent M D 15,000 3,723,231
2018-01-09 4 Jacobsen S. Chris S D 56.50 -2,500 19,033 1,075,364
2018-01-08 4 Jacobsen S. Chris F D 57.16 -3,651 21,533
2018-01-08 4 Jacobsen S. Chris M D 10,000 25,184
2018-01-09 4 Colosi Scott Matthew S D 56.43 -22,403 56,971 3,214,874
2018-01-08 4 Colosi Scott Matthew F D 57.16 -17,597 79,374
2018-01-08 4 Colosi Scott Matthew M D 40,000 96,971
2018-01-08 4 MOORE GREGORY N M D 8,500 87,650
2018-01-08 4 PARKER JAMES F M D 8,500 92,060
2018-01-08 4 ZARLEY JAMES R M D 8,500 147,200
2018-01-08 4 WIDMER KATHY M D 8,500 18,950
2017-12-15 4 ZARLEY JAMES R Zarley Family Foundation G I 5,000 34,700
2017-12-15 4 ZARLEY JAMES R G D -5,000 130,200
2017-12-15 4 Taylor Wayne Kent G D -100,000 3,708,231
2017-12-12 4 WIDMER KATHY S D 50.86 -1,300 10,450 531,487
2017-12-08 4 Taylor Wayne Kent S D 50.61 -100,000 3,808,231 192,734,571
2017-12-07 4 Taylor Wayne Kent S D 51.09 -200,000 3,908,231 199,671,522
2017-11-13 4 Catlett Celia S D 49.34 -3,663 6,337 312,668
2017-11-03 4 Colosi Scott Matthew G D -3,087 56,971
2017-09-21 4 WIDMER KATHY S D 47.95 -2,000 11,750 563,412
2017-08-11 4 Jacobsen S. Chris S D 49.25 -2,500 15,184 747,812
2017-05-31 4 WIDMER KATHY S D 48.97 -5,200 13,750 673,338
2017-05-09 4 Catlett Celia S D 49.95 -1,837 10,000 499,500
2017-05-09 4 Colosi Scott Matthew S D 49.54 -10,000 60,058 2,975,273
2017-05-02 4 Catlett Celia S D 50.80 -5,000 11,837 601,320
2017-05-03 4 Jacobsen S. Chris S D 51.29 -3,500 17,684 907,012
2017-03-27 4 WIDMER KATHY S D 43.17 -4,800 18,950 818,072
2017-03-02 4 MOORE GREGORY N Moore Family Trust G I 8,500 79,150
2017-03-02 4 MOORE GREGORY N G D -8,500 0
2017-02-27 4 Jacobsen S. Chris F D 42.22 -755 21,184
2017-02-27 4 Jacobsen S. Chris M D 2,125 21,939
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Texas Roadhouse: Growth Set To Continue

2018-05-08 seekingalpha
Strong revenue growth over the last several years displays combination of consumer demand, as well as effective management performance. (1-0)

Short Squeeze Launches Shake Shack Shares Into Nosebleed Territory

2018-05-04 seekingalpha
The beauty of the dining sector is that investors can usually fairly easily understand and value public companies. Sometimes, stocks like Shake Shack (SHAK) develop a cult following on the long side and/or a sizable short seller community that looks at the underlying numbers and sees that things don't add up. The shorts are likely helping drive Friday's more than 20% surge in SHAK stock, after the company reported first quarter same store sales of +1. (42-2)

Top Analyst Upgrades and Downgrades: Alcoa, Apple, Brinker, Crocs, Nuvasive, Texas Roadhouse, Under Armor and More

2018-05-02 247wallst
The futures traded slightly lower Wednesday morning as investors digest Tuesday’s roller-coaster market ride. Those seem to be becoming more and more common. The selling this time was sparked by some weak economic data, causing some to think that perhaps growth is slowing. (212-0)

Stocks making the biggest moves premarket: MRK, PFE, AAPL, UAA, FB, BA & more

2018-05-01 cnbc
Merck – The drugmaker beat estimates by 5 cents a share, with adjusted first-quarter profit of $1.05 per share. Revenue was very slightly below forecasts. Merck's results were powered by strong growth in sales of its cancer drug Keytruda, an it also raised its earnings forecast for the year. (62-0)

Top Analyst Upgrades and Downgrades: AK Steel, Arconic, Facebook, Inogen, Roku, Sprint, SteadyMed and More

2018-05-01 247wallst
Stocks closed lower on Monday as profit-taking prevailed over positive earnings and good economic news, and the market indices were looking for direction on Tuesday. Investors have noticed that selling pressure around profit-taking and volatility fears have overcome the dominance of the “buy the sell-offs” mentality. The bull market is also over nine years old and has run into a tired spell. Now investors are wondering how to position their assets and investments for the rest of 2018 and beyond. (126-0)